Evidence map›Paper›PMID 39051328›Full record

ArticleAntibodies (Basel, Switzerland)2024

Characterization of the Charge Heterogeneity of a Monoclonal Antibody That Binds to Both Cation Exchange and Anion Exchange Columns under the Same Binding Conditions.

Ming-Ching Hsieh, Jingming Zhang, Liangjie Tang, Cheng-Yen Huang, Yang Shen, Alice Matathia, Jun Qian, Babita Saxena Parekh

Abstract read
In one paragraph

Article in Antibodies (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ming-Ching HsiehAnalytical Sciences, Eli Lilly and the Company, Branchburg, NJ 08876, USA.
Jingming ZhangAnalytical Sciences, Eli Lilly and the Company, Branchburg, NJ 08876, USA.
Liangjie TangAnalytical Development, Eli Lilly and the Company, Indianapolis, IN 46221, USA.
Cheng-Yen HuangAnalytical Sciences, Eli Lilly and the Company, Branchburg, NJ 08876, USA.
Yang ShenAntibody Technology, Eli Lilly and the Company, New York, NY 10016, USA.ORCID 0009-0005-2434-964X
Alice MatathiaTS/MS Laboratories, Eli Lilly and the Company, Branchburg, NJ 08876, USA.
Jun QianAnalytical Development, Eli Lilly and the Company, Indianapolis, IN 46221, USA.
Babita Saxena ParekhAnalytical Sciences, Eli Lilly and the Company, Branchburg, NJ 08876, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic antibodies play an important role in the public healthcare system to treat patients with a variety of diseases. Protein characterization using an array of analytical tools provides in-depth information for drug quality, safety, efficacy, and the further understanding of the molecule. A therapeutic antibody candidate MAB1 exhibits unique binding properties to both cation and anion exchange columns at neutral pH. This uniqueness disrupts standard purification processes and necessitates adjustments in manufacturing. This study identifies that the charge heterogeneity of MAB1 is primarily due to the N-terminal cyclization of glutamine to pyroglutamine and, to a lesser extent, succinimide intermediate, deamidation, and C-terminal lysine. Using three approaches, i.e., deferential chemical labeling, H/D exchange, and molecular modeling, the binding to anion exchange resins is attributed to negatively charged patches on the antibody's surface, involving specific carboxylic acid residues. The methodologies shown here can be extended to study protein binding orientation in column chromatography.

Indexed as

anion exchangecation exchangecharge heterogeneitychemical labelinghydrogen–deuterium (H/D) exchange mass spectrometrymolecular modelingmonoclonal antibody

Identifiers

PMID39051328
PMCPMC11270306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.